+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Preventive Vaccine Market 2020-2026

  • PDF Icon


  • May 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129777
Global Preventive Vaccine Market Size, Share & Trends Analysis Report, By Vaccine Type (Live-Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines, Toxoid Vaccines and Others), By Patient (Pediatric and Adults), and Forecast, 2020-2026
The preventive vaccine market is expected to show a lucrative growth at a CAGR of around 9.0% during the forecast period 2020-2026. Major factors for the growth of the market include increasing healthcare expenditure and rising awareness for vaccination in the emerging economies. Besides, government funding for vaccination, the new development of the vaccines is also augmenting the vaccination market. Moreover, exponential growth in the preventive vaccine market will be witnessed all over the globe due to the COVID-19 pandemic. The companies are trying to develop vaccines for the COVID-19 as early as possible.

The global preventive vaccine market is segmented based on vaccine type and patient. Based on the vaccine type, the market is divided into live-attenuated vaccines, inactivated vaccines, subunit, recombinant, polysaccharide, & conjugate vaccines, toxoid vaccines, and others. Inactivated vaccines are expected to show significant growth during the forecast period. On the basis of the patient, the market is classified into pediatric and adults vaccines. In 2019, the pediatric vaccine is expected to hold a major market share. The global preventive vaccine market is segmented based on four major regions, including North America (the US and Canada), Europe (Germany, UK, France, Italy, and Spain), Asia-Pacific (China, Japan, India), and the Rest of the World (RoW). The US is expected to hold a significant market for whereas Asia-Pacific will show a lucrative growth rate during the forecast period. China and India will be among the fastest-growing market during the forecast period.

The major players operating in the market include Sanofi SA, GlaxoSmithKline PLC, CSL Ltd., Merck & Co., Inc., Pfizer Inc., Gilead Sciences, Inc., Astellas Pharma Inc., AstraZeneca plc, China National Biotec Group Company Ltd., Emergent BioSolutions Inc., Mitsubishi Tanabe Pharma Corp., Teva Pharmaceutical Industries Ltd. In order to gain a competitive edge over competitors, the market players are adopting growth strategies, including mergers & acquisitions, product launches, and partnerships & collaborations.

Research Methodology

The market study of the global preventive vaccine market is incorporated by extensive primary and secondary research. Secondary research has been conducted to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts to amplify the added validity of the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market
  • Authentic public databases
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report provides in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:
  • Global Preventive Vaccine Market Research and Analysis, By Vaccine Type
  • Global Preventive Vaccine Market Research and Analysis, By Patient

The Report covers:
  • Comprehensive research methodology of the Global Preventive Vaccine Market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global Preventive Vaccine Market.
  • Insights about market determinants which are stimulating the Global Preventive Vaccine Market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdowns
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. GlaxoSmithKline PLC Overview Financial Analysis SWOT Analysis Recent Developments
3.3.2. Sanofi SA Overview Financial Analysis SWOT Analysis Recent Developments
3.3.3. Merck & Co., Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.4. Pfizer Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.5. CSL Ltd. Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Preventive Vaccine Market by Vaccine Type
5.1.1. Live-Attenuated Vaccines
5.1.2. Inactivated Vaccines
5.1.3. Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
5.1.4. Toxoid Vaccines
5.1.5. Other (DNA Vaccines and Recombinant Vector Vaccines)
5.2. Global Preventive Vaccine Market by Patient
5.2.1. Pediatric
5.2.2. Adults
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Astellas Pharma Inc.
7.2. AstraZeneca plc
7.3. Bavarian Nordic A/S
7.4. China National Biotec Group Company Ltd.
7.5. CSL Ltd.
7.6. Emergent BioSolutions Inc.
7.7. F. Hoffmann-La Roche Ltd.
7.8. Gilead Sciences, Inc.
7.9. GlaxoSmithKline PLC
7.10. Inovio Pharmaceuticals, Inc.
7.11. Johnson & Johnson Services, Inc.
7.12. Merck & Co., Inc.
7.13. Mitsubishi Tanabe Pharma Corp.
7.14. Novavax, Inc.
7.15. Pfizer Inc.
7.16. Sanofi SA
7.17. SELLAS Life Sciences Group, Inc.
7.18. Serum Institute of India Pvt. Ltd.
7.19. Sun Pharmaceutical Industries Ltd.
7.20. Takeda Pharmaceutical Co. Ltd.
7.21. Teva Pharmaceutical Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bavarian Nordic A/S
  • China National Biotec Group Company Ltd.
  • CSL Ltd.
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • SELLAS Life Sciences Group, Inc.
  • Serum Institute of India Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.